Literature DB >> 16420434

Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.

Masuo Ohno1, Lei Chang, Wilbur Tseng, Holly Oakley, Martin Citron, William L Klein, Robert Vassar, John F Disterhoft.   

Abstract

Transgenic mouse models of Alzheimer's disease (AD) exhibit amyloid-beta (Abeta) accumulation and related cognitive impairments. Although deficits in hippocampus-dependent place learning have been well characterized in Alzheimer's transgenic mice, little is known about temporal memory function in these AD models. Here, we applied trace fear conditioning to two different Alzheimer's mouse models and investigated the relationship between pathogenic Abeta and temporal memory deficits. This behavioral test requires hippocampus-dependent temporal memory processing as the conditioned and unconditioned stimuli are separated by a trace interval of 30 s. We found that both amyloid precursor protein (APP) transgenic (Tg2576) and APP/presenilin (PS)1 transgenic (Tg6799) mice were impaired in memorizing this association across the time gap. Both transgenic groups performed as well as wild-type control mice in delay fear conditioning when the trace interval was removed, indicating that the trace conditioning deficits are hippocampus-specific. Importantly, Tg6799 mice engineered to lack the major Alzheimer's beta-secretase (beta-site APP-cleaving enzyme 1: BACE1) showed behavioral rescue from temporal memory deficits. Elevated levels of soluble Abeta oligomers found in Tg6799+ mouse brains returned to wild-type control levels without changes in APP/PS1 transgene expression in BACE1-/- * Tg6799+ bigenic mouse brains, suggesting Abeta oligomers as potential mediators of memory loss. Thus, trace fear conditioning is a useful assay to test the mechanisms and therapeutic interventions for Abeta-dependent deficits in temporal associative memory. Our gene-based approach suggests that lowering soluble Abeta oligomers by inhibiting BACE1 may be beneficial for alleviating cognitive disorders in AD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16420434     DOI: 10.1111/j.1460-9568.2005.04551.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  114 in total

1.  5XFAD mice show early-onset gap encoding deficits in the auditory cortex.

Authors:  Aldis P Weible; Amanda J Stebritz; Michael Wehr
Journal:  Neurobiol Aging       Date:  2020-06-01       Impact factor: 4.673

2.  Mitochondrial dysfunction and accumulation of the β-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice.

Authors:  Latha Devi; Masuo Ohno
Journal:  Neurobiol Dis       Date:  2011-09-13       Impact factor: 5.996

3.  The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo.

Authors:  Lujia Zhou; Soraia Barão; Mathias Laga; Katrijn Bockstael; Marianne Borgers; Harry Gijsen; Wim Annaert; Diederik Moechars; Marc Mercken; Kris Gevaert; Kris Gevaer; Bart De Strooper
Journal:  J Biol Chem       Date:  2012-06-12       Impact factor: 5.157

4.  Aβ neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors.

Authors:  Haitao You; Shigeki Tsutsui; Shahid Hameed; Thomas J Kannanayakal; Lina Chen; Peng Xia; Jordan D T Engbers; Stuart A Lipton; Peter K Stys; Gerald W Zamponi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

5.  A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease.

Authors:  Hiroaki Fukumoto; Hideki Takahashi; Naoki Tarui; Junji Matsui; Taisuke Tomita; Mitsuhiro Hirode; Masumi Sagayama; Ryouta Maeda; Makiko Kawamoto; Kazuko Hirai; Jun Terauchi; Yasufumi Sakura; Mitsuru Kakihana; Kaneyoshi Kato; Takeshi Iwatsubo; Masaomi Miyamoto
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

Review 6.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

7.  Effects of BACE1 haploinsufficiency on APP processing and Aβ concentrations in male and female 5XFAD Alzheimer mice at different disease stages.

Authors:  L Devi; M Ohno
Journal:  Neuroscience       Date:  2015-08-24       Impact factor: 3.590

Review 8.  Targeting the β secretase BACE1 for Alzheimer's disease therapy.

Authors:  Riqiang Yan; Robert Vassar
Journal:  Lancet Neurol       Date:  2014-02-17       Impact factor: 44.182

Review 9.  Alzheimer's disease as homeostatic responses to age-related myelin breakdown.

Authors:  George Bartzokis
Journal:  Neurobiol Aging       Date:  2009-09-22       Impact factor: 4.673

Review 10.  β-Secretase: its biology as a therapeutic target in diseases.

Authors:  Haibo Wang; Rena Li; Yong Shen
Journal:  Trends Pharmacol Sci       Date:  2013-02-27       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.